

# Product Datasheet

## Fc gamma RI/CD64 Antibody (H22) [DyLight 488] NBP2-81098G

Unit Size: 0.1 ml

Store at 4C in the dark.

[www.novusbio.com](http://www.novusbio.com)



[technical@novusbio.com](mailto:technical@novusbio.com)

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:  
[www.novusbio.com/NBP2-81098G](http://www.novusbio.com/NBP2-81098G)

Updated 7/11/2023 v.20.1

Earn rewards for product  
reviews and publications.

Submit a publication at [www.novusbio.com/publications](http://www.novusbio.com/publications)

Submit a review at [www.novusbio.com/reviews/destination/NBP2-81098G](http://www.novusbio.com/reviews/destination/NBP2-81098G)



**NBP2-81098G**

Fc gamma RI/CD64 Antibody (H22) [DyLight 488]

Product Information	
Unit Size	0.1 ml
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	H22
Preservative	0.05% Sodium Azide
Isotype	IgG Kappa
Conjugate	DyLight 488
Purity	Protein A purified
Buffer	50mM Sodium Borate
Product Description	
Host	Rabbit
Gene ID	2209
Gene Symbol	FCGR1A
Species	Human
Specificity/Sensitivity	This immunotoxin is specific for human Fc gamma RI/CD64, and specifically an epitope outside the Fc binding domain. The binding activity of the VH/VL antibody format was unaffected by fusion of the m22(scFv) coding regions to the truncated ETA coding sequences
Immunogen	This recombinant antibody was prepared by cloning the single chain fragment (scFv) derived from the murine anti-human Fc gamma RI/CD64 mAb m22 into the bacterial expression vector pBM1.1, and fusing it to a deletion mutant of Pseudomonas exotoxin A.
Notes	DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
Product Application Details	
Applications	Flow Cytometry, Immunocytochemistry/Immunofluorescence, Competitive ELISA
Recommended Dilutions	Flow Cytometry, Immunocytochemistry/Immunofluorescence, Competitive ELISA
Application Notes	Optimal dilution of this antibody should be experimentally determined. This antibody binds human CD64 and can be bound to a toxin so that together it displays specific cytotoxicity, and thus can be used to selectively eliminate AML cells; FC analysis indicated that this immunotoxin drove 41% of primary leukemia cells from a patient with CD64-positive AML into early apoptosis (Tur, 2003). Similarly, in an in vivo mouse model, IHC analysis revealed efficient elimination of human CD64+ tumor cells in mouse organs (Tur, 2011).





### **Novus Biologicals USA**

10730 E. Briarwood Avenue  
Centennial, CO 80112  
USA  
Phone: 303.730.1950  
Toll Free: 1.888.506.6887  
Fax: 303.730.1966  
nb-customerservice@bio-techne.com

### **Bio-Techne Canada**

21 Canmotor Ave  
Toronto, ON M8Z 4E6  
Canada  
Phone: 905.827.6400  
Toll Free: 855.668.8722  
Fax: 905.827.6402  
canada.inquires@bio-techne.com

### **Bio-Techne Ltd**

19 Barton Lane  
Abingdon Science Park  
Abingdon, OX14 3NB, United Kingdom  
Phone: (44) (0) 1235 529449  
Free Phone: 0800 37 34 15  
Fax: (44) (0) 1235 533420  
info.EMEA@bio-techne.com

### **General Contact Information**

www.novusbio.com  
Technical Support: nb-technical@bio-  
techne.com  
Orders: nb-customerservice@bio-techne.com  
General: novus@novusbio.com

### **Products Related to NBP2-81098G**

---

210-TA-005	TNF-alpha [Unconjugated]
1257-FC-050	Fc gamma RI/CD64 [Unconjugated]
D6050	IL-6 [HRP]
285-IF-100	IFN-gamma [Unconjugated]

---

### **Limitations**

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit [www.novusbio.com/guarantee](http://www.novusbio.com/guarantee)

Earn gift cards/discounts by submitting a review: [www.novusbio.com/reviews/submit/NBP2-81098G](http://www.novusbio.com/reviews/submit/NBP2-81098G)

Earn gift cards/discounts by submitting a publication using this product:  
[www.novusbio.com/publications](http://www.novusbio.com/publications)

